Every material Form 8-K DataMeds AI, Inc. has filed with the SEC since October 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On November 3, 2026, DataMEDS AI terminated its Second Amended and Restated Letter of Intent dated October 19, 2026, effective immediately. The letter of intent covered IP acquisitions, a PharmacyChain license expansion, a controlling stake in Tollo Health, and REBOOT licensing, all to be paid in Company common stock, so shareholders would no longer face the share issuances it contemplated.
Termination notices went to EOS, Scilex, Datavault, HBA, THI and REBOOT on November 3, 2026, effective immediately.
The press release says the Company owes no fees or obligations as a result of the termination and will not issue any shares under the letter of intent.
The REBOOT GLP-1 license dated October 13, 2026 and the Datavault PharmacyChain agreement dated November 24, 2025 remain in full force and effect.
DataMEDS AI entered into a non-binding Second Amended and Restated Letter of Intent dated October 19, 2026, with EOS, Scilex, Datavault AI, HealthBridge Advisors and others to acquire QLPM intellectual property, expand a Datavault AI license, and take a controlling interest in Tollo Health, paid in company stock. The filing says existing public stockholders are expected to hold about 10.5% after closing, so the deal would substantially dilute current shareholders. Closing still requires definitive agreements, stockholder and Nasdaq approvals, and other conditions.
Target post-closing ownership: EOS 14.9%, Scilex 14.9%, Datavault 19.9%, Fortitude 5%, HBA and THI 24.9%, REBOOT 9.9%; existing public holders about 10.5%
Closing requires a liability threshold of not more than $2,000,000 and stockholder and Nasdaq approvals
Company agreed to reimburse Scilex, Datavault and EOS up to $250,000 in legal fees, payable at Closing
Exclusivity runs through November 30, 2026; Gerald Commissiong to serve as Interim Co-Chief Executive Officer
Nasdaq notified DataMeds AI on October 19, 2026 that the company has regained compliance with the $2.5 million minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The company had reported a stockholders' deficit of $(12,447,801) in its 2025 annual report, which led to a deficiency letter in April 2026. The company said it could still be subject to delisting if it does not evidence compliance in its next periodic report.
Deficiency letter received April 13, 2026, after stockholders' equity of $(12,447,801) was reported for the fiscal year ended December 31, 2025
Nasdaq notified the company on June 9, 2026 that it had regained bid-price compliance and granted more time on the equity requirement
Nasdaq compliance notice dated October 19, 2026 confirmed the company met the $2.5 million equity minimum
Company states it may be subject to delisting if it fails to evidence compliance upon filing its next periodic report
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every DataMeds AI, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →